Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Long

Showing results (461-470 of 703) with videos related to

Pageof 71
Sort By:
Journal of Translational Medicine|April 13, 2023
Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approachYizhe Mao, Tuba N Gide, Nurudeen A Adegoke, et al.
Cell|September 9, 2017
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 ImmunotherapyAntoni Ribas, Reinhard Dummer, Igor Puzanov, et al.
The Lancet. Oncology|February 2, 2015
Expanded access programmes: patient interests versus clinical trial integrityPaul Lorigan, Paolo A Ascierto, Reinhard Dummer, et al.
Nature Medicine|October 16, 2023
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Cancer Immunology Research|March 22, 2019
CD96 Is an Immune Checkpoint That Regulates CD8<sup>+</sup> T-cell Antitumor FunctionDeepak Mittal, Ailin Lepletier, Jason Madore, et al.
The Lancet. Oncology|October 12, 2012
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialGeorgina V Long, Uwe Trefzer, Michael A Davies, et al.
NPJ Precision Oncology|July 18, 2024
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumabHelen Gogas, Shruthi Ravimohan, Antara Datta, et al.
The New England Journal of Medicine|June 20, 2024
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaGeorgina V Long, Axel Hauschild, Mario Santinami, et al.
The Lancet. Oncology|March 28, 2024
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysisRobert C Stassen, Carolien C H M Maas, Astrid A M van der Veldt, et al.
Journal for Immunotherapy of Cancer|September 12, 2022
Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sitesJordan W Conway, Robert V Rawson, Serigne Lo, et al.
Pageof 71

Showing results (461-470 of 703) with videos related to

Sort By:
Pageof 71
Journal of Translational Medicine|April 13, 2023
Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approachYizhe Mao, Tuba N Gide, Nurudeen A Adegoke, et al.
Cell|September 9, 2017
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 ImmunotherapyAntoni Ribas, Reinhard Dummer, Igor Puzanov, et al.
The Lancet. Oncology|February 2, 2015
Expanded access programmes: patient interests versus clinical trial integrityPaul Lorigan, Paolo A Ascierto, Reinhard Dummer, et al.
Nature Medicine|October 16, 2023
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trialJohn M Kirkwood, Michele Del Vecchio, Jeffrey Weber, et al.
Cancer Immunology Research|March 22, 2019
CD96 Is an Immune Checkpoint That Regulates CD8<sup>+</sup> T-cell Antitumor FunctionDeepak Mittal, Ailin Lepletier, Jason Madore, et al.
The Lancet. Oncology|October 12, 2012
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialGeorgina V Long, Uwe Trefzer, Michael A Davies, et al.
NPJ Precision Oncology|July 18, 2024
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumabHelen Gogas, Shruthi Ravimohan, Antara Datta, et al.
The New England Journal of Medicine|June 20, 2024
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaGeorgina V Long, Axel Hauschild, Mario Santinami, et al.
The Lancet. Oncology|March 28, 2024
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysisRobert C Stassen, Carolien C H M Maas, Astrid A M van der Veldt, et al.
Journal for Immunotherapy of Cancer|September 12, 2022
Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sitesJordan W Conway, Robert V Rawson, Serigne Lo, et al.
Pageof 71